iwCLL 2017 | Enhancing immunotherapy for CLL patients with ibrutinib
Meixiao Long
• 14 Aug 2017
Meixiao Long, MD from the Ohio State University, Columbus, OH discusses his work on immune modulating therapies for chronic lymphocytic leukemia (CLL) at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 held in New York, NY. His work is based on modulating T-cell immunity to essentially improve T-cell immunotherapy. Dr Long highlights some of his findings from his study on ibrutinib. His main finding is how ibrutinib can promote persistence of T-cells. This finding is not of any significance on its own. However if ibrutinib is combined with for e.g. tumour targeting T-cells such as CAR T-cells, it could definitely enhance the effect of this mode of immunotherapy and many others.
